COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS

被引：0
|
作者：
Cavusoglu, Y. [1 ]
Demir, O. [2 ]
Dinc, M. [3 ]
Ozsoy, A. [3 ]
Erdogan, A. [3 ]
Ozer, S. [4 ]
机构：
[1] Eskisehir Osmangazi Univ, Fac Med, Istanbul 34, Turkey
[2] Ankara Univ, Fac Med, Ankara, Turkey
[3] AstraZeneca, Istanbul, Turkey
[4] Omega CRO, Ankara, Turkey
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA166
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE
    Declan, L.
    Tang, Z. X.
    Ng, C.
    Tan, J.
    Trueman, D.
    Woodcock, F.
    Cristino, J.
    VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [22] Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States
    Zueger, Patrick M.
    Kumar, Varun M.
    Harrington, Rachel L.
    Rigoni, Gianna C.
    Atwood, Alicia
    DiDomenico, Robert J.
    Touchette, Daniel R.
    PHARMACOTHERAPY, 2018, 38 (05): : 520 - 530
  • [23] Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States
    Reifsnider, Odette S.
    Tafazzoli, Ali
    Linden, Stephan
    Ishak, Jack
    Rakonczai, Pal
    Stargardter, Matthew
    Kuti, Effie
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (04):
  • [24] A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
    Tafazzoli, Ali
    Reifsnider, Odette S.
    Bellanca, Leana
    Ishak, Jack
    Carrasco, Marc
    Rakonczai, Pal
    Stargardter, Matthew
    Linden, Stephan
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (09): : 1441 - 1454
  • [25] A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
    Ali Tafazzoli
    Odette S. Reifsnider
    Leana Bellanca
    Jack Ishak
    Marc Carrasco
    Pal Rakonczai
    Matthew Stargardter
    Stephan Linden
    The European Journal of Health Economics, 2023, 24 : 1441 - 1454
  • [26] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
  • [27] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN TURKEY
    Sarioz, F.
    Ozdemir, O.
    Direk, S.
    Caglar, P.
    Ar, I
    VALUE IN HEALTH, 2017, 20 (09) : A616 - A616
  • [28] EVALUATION OF THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN FOR TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE UNITED STATES
    Nechi, R.
    Rane, A.
    Karaye, R.
    Ndikumukiza, C.
    Alsahali, S.
    Jatau, A.
    Zoni, C. R.
    Alanazi, A.
    Karaye, I
    Yunusa, I
    VALUE IN HEALTH, 2023, 26 (06) : S122 - S122
  • [29] Translating findings from the landmark DAPA-HF study: a multinational cost-effectiveness analysis of dapagliflozin in the treatment of heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Mcewan, P.
    Darlington, O.
    Jhund, P.
    Docherty, K.
    Bohm, M.
    Petrie, M.
    Bergenheim, K.
    Qin, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 272 - 273
  • [30] Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 322 : 183 - 190
12345